Core Insights - Biomea Fusion, Inc. has initiated a Phase I clinical trial for BMF-650, a next-generation oral small molecule GLP-1 receptor agonist aimed at treating obesity [1][4] - BMF-650 is designed to enhance oral bioavailability and reduce pharmacokinetic variability, potentially leading to better weight reduction outcomes for patients [2][5] Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, with BMF-650 being a key candidate [11] - The company aims to improve the lives of patients suffering from metabolic diseases through innovative treatments [11] Product Details - BMF-650 has shown promising results in preclinical studies, demonstrating dose-dependent reductions in food intake and significant weight loss in obese cynomolgus monkeys [3][6] - In these studies, animals receiving 10 mg/kg and 30 mg/kg doses experienced average body weight reductions of approximately 12% and 15% respectively [3] - The drug has a favorable pharmacokinetic profile, with higher bioavailability and less inter-individual variability compared to other oral GLP-1 receptor agonists [6] Clinical Development - The Phase I trial will evaluate the safety, tolerability, and preliminary efficacy of BMF-650 in healthy overweight or obese participants, with results expected in the first half of 2026 [4] - Initial data from the trial will focus on 28-day weight loss outcomes at the highest dose [4] Market Context - Obesity is a chronic disease affecting over 40% of adults in the United States, leading to various health complications and a significant public health burden [8] - GLP-1 receptor agonists are recognized for their role in improving glycemic control and promoting weight loss in individuals with type 2 diabetes and obesity [10]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Eccogene Inc. 誠益生物開曼有限公司 * (the "Company") (Incorporated in the Cayman Islands with limited liability) This Applica ...